Get started
Author

Julie Coussirou

Intradermal injection of a Tat Oyi-based therapeutic HIV vaccine reduces of 1.5 log copies/mL the HIV RNA rebound median and no HIV DNA rebound following cART interruption in a phase I/II randomized controlled clinical trial
2016 · Erwann P. Loret, Erwann P. Loret, et al. · Retrovirology · 25
PDF
Erratum to: Intradermal injection of a Tat Oyi-based therapeutic HIV vaccine reduces of 1.5 log copies/mL the HIV RNA rebound median and no HIV DNA rebound following cART interruption in a phase I/II randomized controlled clinical trial
2016 · Erwann P. Loret, Erwann P. Loret, et al. · Retrovirology · 6
PDF
Identification of factors associated with aggressive end-of-life antitumour treatment: retrospective study of 1282 patients with cancer
2020 · Philippe Debourdeau, Mohamed Belkacémi, et al. · BMJ Supportive & Palliative Care · 2
Case Report: Targeted interleukin-6 blockade by siltuximab for cytokine release syndrome control and infection limitation in thirteen patients treated with bi-specific T-cell engagers
2026 · Jean-François Rossi, Thierry Cailleux, et al. · Frontiers in Immunology · 1
PDF
Anti-Cancer Drug-Induced Lyell’s Syndrome: A Series of Two Patients
2024 · Julie Coussirou, Magali Ravoire, et al. · Current Oncology · 1
PDF
Palbociclib in Combination with Endocrine Therapy in Patients with Metastatic Breast Cancer in a Real-World Population: Impact of Dose-Intensity, Dose Reductions and Cycle Delays on Efficacy
2026 · Julie Coussirou, Julien Grenier, et al. · Current Oncology
PDF
Évaluation des besoins pour la mise en place d’une Unité de Thérapie Orale
2022 · Léa Vazquez, Julie Coussirou, et al. · Bulletin du Cancer
Intradermal injection of a Tat Oyi-based therapeutic HIV vaccine significantly reduces levels of HIV RNA and HIV DNA rebound following ART interruption in a phase I/II randomized controlled clinical trial
2016 · Erwann P. Loret, Albert Darque, et al. · Journal of Virus Eradication
PDF
Works count: 8
Citation count: 35
H-index: 2
I10-index: 1
Year
Topic
Type